Teladoc reports $1B net loss in 2024, including $790M impairment charge for BetterHelp. Revenue down 1% to $2.7B, shares fall ...

Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native ...

Kallyope's Phase 2 obesity trial shows K-757 and K-833 combo achieved 2.9% weight loss vs 0.2% for placebo. Results fall ...

Sorriso Pharmaceuticals presents Phase 1b data for SOR102, an oral bispecific antibody for IBD, showing 40% endoscopic ...

Hansoh exits siRNA deal with Silence Therapeutics, Vir seeks partner for hep B combo, Alopexx plans IPO, Medigene-EpimAb partner on T cell engagers, Belite Bio trial cleared ...

Merck, Granules India, Bavarian Nordic lead manufacturing updates. News includes facility builds, acquisitions, partnerships, and EU's Caribbean investment in pharma manufacturing.

Medicare use of GLP-1 diabetes drugs like Ozempic rose 900% over 5 years, with 2023 spending at $35.8B. HHS report shows ...

AstraZeneca reports positive interim results for camizestrant in Phase 3 SERENA-6 trial, showing PFS benefit in ER-positive ...

Regeneron is now expecting an accelerated approval decision this summer on its T cell engager for one form of lymphoma, while ...

Several small clinical trials have demonstrated that gene therapies have restored hearing in children with a rare form of genetic deafness.

Ginkgo Bioworks’ stock $DNA fell by around 13% premarket Wednesday after the company dampened its 2025 sales forecast.

FTC court order requires CVS Health to share more documents about Caremark Rx PBM practices as part of ongoing investigation ...